NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$479.00
Cat.#: 11133 | ||
Product Name: Human CD22 Protein | ||
Size : 10 µg, 50 µg and 100 µg | ||
Synonyms: CD22;SIGLEC2;BL-CAM;SIGLEC-2;Siglec2;SIGLEC2FLJ22814 | ||
Target: CD22 | ||
UNIPROT ID: P20273 | ||
Description: Recombinant human CD22 protein with C-terminal human Fc and 6xHis tag | ||
Background: B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. | ||
Species/Host: HEK293 | ||
Molecular Weight: The protein has a predicted molecular mass of 102.1 kDa after removal of the signal peptide. The apparent molecular mass of CD22-hFc-His is approximately 130-180 kDa due to glycosylation. | ||
Molecular Characterization: CD22(Asp20-Arg687) hFc(Glu99-Ala330) 6×His tag | ||
Purity: The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. | ||
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. | ||
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. | ||
|